Want to join the conversation?
$ICPT 2Q15 Call: We’ll target enrollment of 1400 NASH patients with stage II/III fibrosis. After 72 weeks of treatment these patients will undergo liver biopsy & interim analysis will be performed. Histology data collected in these patients will form basis for anticipated accelerated approval filing to market OCA for treatment of NASH with fibrosis
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.